BioNTech SE (LON:0A3M)
United Kingdom · Delayed Price · Currency is GBP · Price in USD 87.00
-1.16 (-1.32%)
At close: Nov 10, 2026
BioNTech SE Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,420 | 2,870 | 2,751 | 3,819 | 17,311 | 18,977 | |
Revenue Growth | -23.23% | 4.32% | -27.96% | -77.94% | -8.78% | 3834.63% |
Cost of Revenue | 563.1 | 611.3 | 541.3 | 599.8 | 2,995 | 2,912 |
Gross Profit | 1,857 | 2,259 | 2,210 | 3,219 | 14,316 | 16,065 |
Selling, General & Admin | 745 | 624.4 | 599 | 557.7 | 541.2 | 327.2 |
Research & Development | 2,174 | 2,105 | 2,254 | 1,783 | 1,537 | 949.2 |
Other Operating Expenses | 280.7 | 796 | 642.1 | -93.4 | 319.1 | -57.7 |
Operating Expenses | 3,199 | 3,525 | 3,495 | 2,247 | 2,397 | 1,219 |
Operating Income | -1,342 | -1,267 | -1,286 | 971.8 | 11,918 | 14,847 |
Interest Expense | -14.5 | -14.2 | -16.9 | -7.5 | -18.9 | -27.3 |
Interest & Investment Income | 257.1 | 262.6 | 437.6 | 330.9 | - | 1.5 |
Currency Exchange Gain (Loss) | 14.9 | -97.3 | 100.4 | -267.9 | 792.4 | 512.5 |
Other Non Operating Income (Expenses) | 123.6 | 151 | 200.4 | 161.5 | 265.3 | -277.8 |
EBT Excluding Unusual Items | -960.9 | -964.6 | -564 | 1,189 | 12,957 | 15,055 |
Gain (Loss) on Sale of Investments | 9.6 | 3.1 | - | 26.7 | - | - |
Asset Writedown | -349.1 | -30.5 | - | - | - | - |
Legal Settlements | -52.1 | -73.8 | -113.7 | -29.4 | -3 | -9 |
Other Unusual Items | - | 15 | - | - | - | - |
Pretax Income | -1,432 | -1,051 | -677.7 | 1,186 | 12,954 | 15,046 |
Income Tax Expense | 41 | 85.3 | -12.4 | 255.8 | 3,520 | 4,754 |
Earnings From Continuing Operations | -1,473 | -1,136 | -665.3 | 930.3 | 9,434 | 10,293 |
Net Income to Company | - | -1,136 | -665.3 | 930.3 | 9,434 | 10,293 |
Net Income | -1,473 | -1,136 | -665.3 | 930.3 | 9,434 | 10,293 |
Net Income to Common | -1,473 | -1,136 | -665.3 | 930.3 | 9,434 | 10,293 |
Net Income Growth | - | - | - | -90.14% | -8.34% | 67613.82% |
Shares Outstanding (Basic) | 250 | 242 | 240 | 241 | 243 | 244 |
Shares Outstanding (Diluted) | 250 | 242 | 240 | 243 | 250 | 260 |
Shares Change | 4.29% | 0.54% | -0.95% | -2.84% | -3.81% | 4.51% |
EPS (Basic) | -5.89 | -4.70 | -2.77 | 3.87 | 38.78 | 42.18 |
EPS (Diluted) | -5.89 | -4.70 | -2.77 | 3.83 | 37.77 | 39.63 |
EPS Growth | - | - | - | -89.86% | -4.69% | 65950.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -439 | 280.9 | -78.8 | 5,121 | 13,248 | 762.2 |
Free Cash Flow Per Share | -1.75 | 1.16 | -0.33 | 21.10 | 53.03 | 2.94 |
Gross Margin | 76.73% | 78.70% | 80.32% | 84.29% | 82.70% | 84.66% |
Operating Margin | -55.45% | -44.14% | -46.73% | 25.45% | 68.85% | 78.23% |
Profit Margin | -60.87% | -39.59% | -24.18% | 24.36% | 54.50% | 54.24% |
Free Cash Flow Margin | -18.14% | 9.79% | -2.86% | 134.10% | 76.53% | 4.02% |
EBITDA | -1,016 | -1,124 | -1,175 | 1,110 | 11,983 | 14,893 |
EBITDA Margin | -41.99% | -39.17% | -42.69% | 29.07% | 69.22% | 78.48% |
D&A For EBITDA | 325.7 | 142.6 | 111 | 138.2 | 64.5 | 46.2 |
EBIT | -1,342 | -1,267 | -1,286 | 971.8 | 11,918 | 14,847 |
EBIT Margin | -55.45% | -44.14% | -46.73% | 25.45% | 68.85% | 78.23% |
Effective Tax Rate | - | - | - | 21.57% | 27.17% | 31.60% |
Revenue as Reported | - | - | - | - | - | 18,977 |